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ABSTRACT
Background The SARS- CoV-2 pandemic is a global 
health problem. Beside the specific pathogenic effect 
of SARS- CoV-2, incompletely understood deleterious 
and aberrant host immune responses play critical roles 
in severe disease. Our objective was to summarise the 
available information on the pathophysiology of COVID-19.
Methods Two reviewers independently identified eligible 
studies according to the following PICO framework: 
P (population): patients with SARS- CoV-2 infection; 
I (intervention): any intervention/no intervention; C 
(comparator): any comparator; O (outcome) any clinical 
or serological outcome including but not limited to 
immune cell phenotype and function and serum cytokine 
concentration.
Results Of the 55 496 records yielded, 84 articles were 
eligible for inclusion according to question- specific 
research criteria. Proinflammatory cytokine expression, 
including interleukin-6 (IL-6), was increased, especially in 
severe COVID-19, although not as high as other states with 
severe systemic inflammation. The myeloid and lymphoid 
compartments were differentially affected by SARS- CoV-2 
infection depending on disease phenotype. Failure to 
maintain high interferon (IFN) levels was characteristic of 
severe forms of COVID-19 and could be related to loss- of- 
function mutations in the IFN pathway and/or the presence 
of anti- IFN antibodies. Antibody response to SARS- CoV-2 
infection showed a high variability across individuals and 
disease spectrum. Multiparametric algorithms showed 
variable diagnostic performances in predicting survival, 
hospitalisation, disease progression or severity, and 
mortality.
Conclusions SARS- CoV-2 infection affects both humoral 
and cellular immunity depending on both disease severity 
and individual parameters. This systematic literature review 
informed the EULAR ‘points to consider’ on COVID-19 
pathophysiology and immunomodulatory therapies.
INTRODUCTION
The SARS- CoV-2 pandemic has led to the 
scientific and global communities facing an 
unprecedented challenge.1 The rapid spread 
of the virus along with the lack of effective 
antiviral drugs to treat COVID-19 has so far 
resulted in more than 65 000 000 confirmed 
cases and 1 500 000 deaths ( COVID- 19. who. 
int/; 15 December 2020).2 SARS- CoV-2 
Key messages
What is already known about this subject?
 ► The SARS- CoV-2 pandemic is a global health is-
sue and disease pathogenesis along with mech-
anisms leading to severe COVID-19 are yet poorly 
understood.
 ► A deleterious excessive and aberrant non- effective 
host immune response may play an important role 
throughout the course of severe disease.
What does this study add?
 ► Cytokine profiles, cellular and humoral immune re-
sponse are highly heterogeneous across individuals 
and specific patterns are associated with the evolu-
tion to severe COVID-19 and a poor prognosis.
 ► Failure to maintain high interferon (IFN) levels is 
characteristic of severe forms of COVID-19 and 
could be related to loss- of- function mutations in 
the IFN pathway and/or the presence of anti- IFN 
antibodies.
 ► Immune and non- immune- mediated mechanisms 
play an important role in COVID-19 thrombotic 
manifestations.
 ► Multiparametric algorithms including clinical and 
biological features can predict poor outcomes in 
SARS- CoV-2 infected individuals.
How might this impact on clinical practice?
 ► The emerging knowledge on immune pathways and 
severe SARS- CoV-2 infection indicate distinct cy-
tokine pathway perturbations compared with other 
rheumatological disorders including the interleu-
kin-6 and type I IFN pathway.
 ► Significant knowledge gaps exist that will stimulate 
further research.
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infection encompasses a broad spectrum of clinical 
phenotypes, from asymptomatic or mild diseases with 
little or no respiratory symptoms to severe COVID-19 
with life- threatening manifestations such as acute respira-
tory distress syndrome (ARDS) leading to multiorgan 
failure and death.3 Lung damage in severe COVID-19 is 
linked to inflammatory alveolar and interstitial immune 
cell infiltration and activation.4 The cellular and humoral 
immune response to SARS- CoV-2 appears to inadequately 
control viral spread or may be evident in tissue where 
there is no detectable virus with both scenarios being 
potentially deleterious consequent to severe inflamma-
tion.5 Excessive production and release of proinflam-
matory mediators, including interleukin (IL)-1β, IL-6, 
tumour necrosis factor-α and monocyte chemoattractant 
protein 1 (MCP-1) and many other molecules, occurs in 
more patients with severe COVID-19.6 In severe cases, 
these features resemble other systemic severe inflam-
matory states such as macrophage activation syndrome 
(MAS) or secondary haemophagocytic lymphohistocy-
tosis.6 7
A massive research effort to better understand the 
complex viral–host interactions has resulted in an 
extremely high volume of publications in a very short 
timeframe. The high heterogeneity and variety in the 
quality of the literature require a systematic appraisal; in 
order to propose a synthesis of existing evidence towards 
improved COVID-19 understanding and therapy. This 
systematic literature review (SLR) aimed to summarise the 
available information on the pathogenesis of SARS- CoV-2 
infection from the rheumatological perspective, given 
that this specialty is intimately involved in investigation 
of aberrant and severe immunological reactions in many 
organ systems and in heterogeneous autoimmune and 
autoinflammatory disorders. An SLR addressing ther-
apeutic aspects on the repurposing of rheumatic drugs 
as potential COVID-19 therapy is addressed elsewhere.8 
This SLR informed the EULAR points to consider (PtC) 




The scope of the systematic literature search on patho-
physiology according to the Population, Intervention, 
Comparator and Outcome (PICO) approach was deter-
mined by the EULAR task force aiming at developing 
PtCs on COVID-19 pathophysiology and immunomodu-
latory therapies (online supplemental text S1).10 Three 
separate searches (online supplemental text S2, S3 and 
S4) were performed, one for studies on pathophysi-
ology of COVID-19, the second on studies on COVID-19 
treatment and the third on COVID-19 and rheumatic 
and musculoskeletal diseases (RMDs), with this SLR 
reporting on pathophysiology. The databases explored 
were MEDLINE, Embase, The Cochrane Database of 
Systematic Reviews, CENTRAL and CINAHL. Hand 
search for individual original research studies and cross-
check for references from specific Rheumatology, Haema-
tology and Immunology journals were selected as described 
in the online supplemental material.
Study selection, data collection and assessment of risk of 
bias
Two reviewers (AA and AN) independently assessed titles 
and abstracts of the retrieved papers. General eligibility 
criteria were described as follows: original research articles, 
published in peer- reviewed journals in English language, 
on adult and paediatric patients with proven SARS- CoV-2 
infection according to the reference standard (nucleic 
acid amplification tests such as RT- qPCR) presenting 
with signs/symptoms of COVID-19 or asymptomatic and 
no diagnosis of RMDs prior to SARS- CoV-2 infection. In 
addition, different predetermined eligibility criteria were 
set according to the research questions (online supple-
mental text S5). Among other, unsupervised clustering 
methods (defined as multiparametric flow cytometry, 
mass cytometry, multiplex- luminex technologies, single 
cell RNA seq) were a pre- requisite for cells population, 
chemokines and cytokines assessment. In addition, for 
humoral response assessment, only studies using vali-
dated commercially available antibodies testing kits 
were included. For multiparametric algorithm studies, 
a minimum size of 200 patients was chosen. The agree-
ment between reviewers, calculated with the Cohen’s 
kappa, was 0.95. Discrepancies were resolved by discus-
sion. The task force methodologist (PMM) was consulted 
in the case of uncertainties. Data on patients’ charac-
teristics, scientific methods, parameters assessed and 
outcomes were extracted. The risk of bias was calculated 
with validated tools according to the study design (online 
supplemental text S6). The structure of reporting this 
SLR follows the structure of the PtCs,8 as decided by the 
task force members following a consensus process.
RESULTS
Of the 55 496 records yielded by the three searches, 290 
were selected for detailed review. Of these, 84 articles met 
the inclusion criteria for the research questions on the 
pathogenesis of COVID-19 (online supplemental table 
S1 and S2).
Genetic variants and SARS-CoV-2 severity
As far as genes involved in the immune response are 
concerned, Zhang et al demonstrated that known vari-
ants of toll- like receptor 3 (TLR3)–and interferon regu-
latory factor 7 (IRF7)–dependent type I interferon (IFN) 
immunity associated with life- threatening influenza 
are present in a subset of patients with life- threatening 
COVID-19 (table 1).11 In addition, new TLR3 variants 
have been identified in life- threatening COVID-19 and 
linked to hampered IFN immunity in vivo and in vitro.11 
Variants of the IFN- related genes were also identified by 
a study sequencing and genotyping interferon- induced 
transmembrane protein 3 (IFITM3) rs12252 sequence 
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Table 1 Genetic variants and disease severity
Author Study type Population
Blood type 
distribution Other findings RoB
Rhesus and ABO





NA  ► rs657152 A or C SNP at locus 9q34.2 (OR for 
the A allele 1.32; 95% CI 1.20 to 1.47; p<0.0001)
 ► Higher risk of severe COVID-19 in blood group 
A vs other blood groups (OR 1.45; 95% CI 1.20 
to 1.75; p=0.0148)
 ► Lower risk of severe COVID-19 in blood group O 
vs other blood groups (OR 0.65; 95% CI 0.53 to 
0.79; p<0.0001)
 ► No significant difference in blood group 
distribution between patients receiving 
supplemental oxygen only and those receiving 
mechanical ventilation of any kind
Low
HLA

























 ► No SNP association signals at the HLA complex that met the 
significance threshold of suggestive association
 ► No significant allele associations with either COVID-19 infection or 
disease severity
High
Genes encoding molecules involved in the host immune response












 ► Association between homozygosity for the C allele (CC vs CT/TT) 
and disease severity (OR 6.37; p<0.0001)
 ► 2 of the 3 patients who died carried the CC genotype
 ► The frequency of CC genotype in mild patients is similar to that in 
the general Beijing population
Unclear







22 severe young COVID-19
vs
22 HD
(14 Latin- American, 7 
Spanish and 1 Polish)
 ► Both A91V- positive patients died High





 ► Cross- replicating associations with rs11385942 at locus 3p21.31 
(spanning the genes LZTFL1, CCR9, FYCO1, CXCR6 and XCR1)
High
Zhang et al11 RNA Seq 659 life- threatening 
COVID-19 pneumonia
vs
534 asymptomatic or 
benign
SARS- CoV-2 infection
 ► Known variants of Toll- like receptor 3 (TLR3)–and interferon 
regulatory factor 7 (IRF7)–dependent type I interferon (IFN) 
immunity associated with life- threatening influenza are present in a 
subset of patients with life- threatening COVID-19
 ► New variants within the same loci have been identified in life- 
threatening COVID-19
 ► Patients showing these variants have hampered IFN immunity in 
vivo and in vitro
Low




 ► Significant associations in a gene cluster encoding antiviral 
restriction enzyme activators (OAS1, OAS2, OAS3) near the gene 
encoding tyrosine kinase 2 (TYK2) and in the interferon receptor 
gene IFNAR2
 ► Using Mendelian randomisation, evidence in support of a causal 
link from low expression of IFNAR2, and high expression of TYK2, 
to life- threatening disease
 ► Transcriptome- wide association in lung tissue revealed that high 
expression of the monocyte/macrophage chemotactic receptor 
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that observed an association between homozygosity 
for the C allele (CC vs CT/TT) and disease severity 
(OR 6.37; p<0.0001).12 A first genome- wide association 
study (GWAS) conducted in 1980 patients with severe 
COVID-19 identified cross- replicating associations with 
rs11385942 at locus 3p21.31 spanning genes involved in 
the immune response such as CCR9, CXCR6 and CXCR1.4 
While writing this manuscript, an important GWAS study 
came to our attention.13 Although outside the review 
period, we highlight it due to its relevance and the excep-
tionality of the rapid pace of publications on the topic of 
this SLR. This GWAS made on 2244 critically ill patients 
revealed association with single nuclear polymorphism 
(SNP) involved in the IFN pathway (IFNAR2, TYK2, OAS) 
and CCR2. Mendelian randomisation supported a causal 
link from low expression of IFNAR2 and high expression 
of TYK2 to life- threatening disease, and high expression 
of CCR2 as well.13 Sequencing and genotyping of perforin 
rs35947132 (A91V) sequence in patients with severe 
COVID-19 was also performed showing that both patients 
carrying the sequence died.14 Of interest, previous 
studies reported a higher prevalence of the A91V variant 
in patients with haemophagocytic lymphohistocytosis,15 
suggesting a possible common mechanism. Data on 
human leucocyte antigen (HLA) haplotypes are scarce 
and only showed a higher prevalence of some haplotypes 
(B*27:07, DRB1*15:01 and DQB1*06:02) in 99 COVID-19 
patients versus 107 healthy donors.16 In addition, the 
only available GWAS failed to identify any SNP associ-
ation signals at the HLA complex that met the signifi-
cance threshold of suggestive association or any signifi-
cant allele associations with either COVID-19 infection or 
disease severity (1980 and 2381 patients, respectively).17
Other genes that are not directly involved in the 
immune response but may be related to SARS- CoV-2 
infection have been explored. The ACE-2 facilitates 
SARS- CoV-2 entry in human cells by binding of the virus 
spike protein.18 Low ACE2 allelic variability has been 
reported,19 20 along with a different distribution of vari-
ants versus controls.19 However, no solid association 
between ACE-2 variants and disease severity has been 
demonstrated.17 19–21 Finally, with regard to blood type, 
the only available data come from a GWAS study which 
identified the rs657152 A or C SNP at locus 9q34.2 (OR 
for the A allele 1.32; 95% CI 1.20 to 1.47; p<0.0001) and 
estimated a higher risk of severe COVID-19 in blood 
group A versus other blood groups and a lower risk of 
severe COVID-19 in blood group O versus other blood 
groups.17 All data pertaining to this research question are 
reported in table 1.
Myeloid cellular response to SAR-CoV-2 infection according 
to disease phenotype
Innate and adaptive cellular immune response has been 
thoroughly assessed. It is worth noting that only a few 
studies used unsupervised clustering approaches (single 
cell RNA sed, Cellular Indexing of Transcriptomes and 
Epitopes by Sequencing (CITE- seq)) while most used 
multiparametric flow cytometry. Since different gating 
strategies were used, different ‘unique’ subsets were 
reported in several studies and are shown in table 2. 
Data detailed in the text were reported in at least two 
individual studies. Neutrophils were reported to be 
overall increased in patients with COVID-19 regardless 
of disease severity versus healthy donor (HD).22 23 Of 
interest, circulating immature neutrophils were reported 
to be increased, similarly to bacterial sepsis.22 The mono-
cyte compartment was affected by SARS- CoV-2 infection 
in different manners. A shift towards classical CD14+ 
inflammatory monocytes producing TNFα and IL-1β was 
observed in all patients with COVID-19 versus HD.22–25 In 
addition, the expression of HLA- DR was strongly reduced, 
Author Study type Population
Blood type 
distribution Other findings RoB





 ► Different distributions of variants vs controls
 ► Lower ACE2 allelic variability vs controls (p value<0.029)
Unclear






 ► No evidence of consistent association of ACE2 variants with 
COVID-19 severity
Unclear
Gomez et al20 ACE2 gene 
seq and SNP 
assessment
204 COVID-19
(137 non- severe and 67 
severe)
vs 536 HD
 ► Low ACE2 allelic variability
 ► ACE I/D DD phenotype more prevalent in severe diseases but not 
significant at multivariable analysis
 ► The ACE2 rs2285666 alleles did not differ based on severity nor vs 
controls
 ► Both polymorphisms are associated with hypertension
Unclear






 ► No evidence identified in ACE-2 loci
 ► Cross- replicating associations with rs11385942 at locus 3p21.31 
(spanning the SLC6A20 gene among others)
High
GWAS, genome- wide association study; HD, healthy donor; HLA, human leucocyte antigens; JAK, Janus kinase; NA, not available; RoB, risk of bias; SNP, single 
nuclear polymorphism; TYK, tyrosine kinase.
Table 1 Continued
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Table 2 Cellular immune response to SARS- CoV-2 infection according to disease phenotype
  Author Study type Patients N Control N Cells RoB
COVID-19 (mild, moderate and/or severe) vs healthy donors
Neutrophils Schulte- Schrepping 
et al22





10 HD ↑ LDN, FUT4(CD15)+ CD63+ CD66b+ pro- 
neutrophils, and ITGAM(CD11b)+ CD101+ pre- 
neutrophils, reminiscent of emergency myelopoiesis,
↑ CD274(PD- L1)+ ZC3H12A+ mature neutrophils 
reminiscent of gMDSC- like cells
Unclear
Silvin et al23 CyTOF, single cell 
RNA seq
13 COVID-19 (mild 5, 
severe 8)
25 HD ↑ neutrophils
↑ CD10LowCD101+ neutrophils in patients with mild 
disease, whereas ↑ CD10LowCD101− neutrophils in 
patients with severe disease
Unclear












↓ HLA- DR and expression of proinflammatory 
cytokines.
Impaired response to stimulation with a bacterial or 
viral ligand cocktail
High




35 (7 moderate, 28 
severe), 7 recovered
12 HD ↓ HLA- DR expression in severe patients High
Lucas et al26 Multiparametric flow 
cytometry
113 (moderate 80, 
severe 33)
108 HD ↓ reduction of HLA- DR monocytes Low
Wen et al24 Multiparametric flow 
cytometry
10 recovered (5 early 
and 5 late)
5 HD ↑ CD14++ IL1β+ monocytes and IFN- activated 
monocytes
High
Lee et al25 ScRNA seq PBMCs 8 COVID-19 (severe, 
mild, asymptomatic), 5 
Influenza
4 HD The TNF/IL-1β-driven inflammatory response was 
dominant in COVID-19 across all types of cells 
among PBMCs
HIgh
Silvin et al23 Cy- TOF, single cell 
RNA seq
13 COVID-19 (mild 5, 
severe 8)
25 HD ↑ CD14HighCD16High intermediate monocytes in 




Cy- TOF, single cell 
RNA seq,
flow cytometry
58 (40 COVID-19, 8 
influenza)
10 HD ↑ inflammatory HLA- DRhiCD11chi CD14+ 
monocytes with an interferon- stimulated gene 
signature in mild forms
↑ HLA- DRhiCD11chi monocytes in severe forms
↓ expression of CD11c and HLA- DRA and HLA- 
DRB1 early and sustained ↑ CD226+ CD69+ 
monocytes
Dysfunctional HLA- DRloCD163hi and HLA- 
















↓ pDCs pool reduced
Impaired mTOR signalling and IFN- a production in 
response to the TLR stimuli and TNF response.
High
Zhou et al32 Multiparametric flow 
cytometry
Patients DC cultures
Acute COVID-19 (6 
severe and 11 mild)
Convalescent 
COVID-19 (2 severe 
and 22 mild)
HD ↑ monocytic myeloid- derived suppressive cells in 
acute patients vs HD
↓ CD11c+ cDCs decreased in convalescent patients
↓ CD86 expression vs HD but not HLA- DR
High





10 HD ↓ CD4+
No difference in any of the subsets (naïve (N) 
(CD45RO- CCR7+ CD28+), central memory (CM) 
(CD45RO+ CCR7+ CD28+), transitional memory 
(TM) (CD45RO+ CCR7 CD28+), effector memory 
(EM) (CD45RO+ CCR7- CD28-), and terminally 
differentiated effector (E) (CD45RO- CCR7- CD28-)
↓ CD8+ (↓ naïve, ↑ effector, effector memory and 
transitional memory cells)
↑ cytotoxic molecules secretion granzyme A in 
effector, effector memory, and transitional memory 
cells and granzyme and perforin in effector memory, 
and transitional memory cells
More multifunctional effector and effector memory 
T cells
High





35 (7 moderate, 28 
severe), 7 recovered
12 HD =across all groups High
Lucas et al26 Multiparametric flow 
cytometry
PBMCs
113 (moderate 80, 
severe 33)
108 HD ↓ CD4+ and CD8+ Low
Wang et al31 CyTOF PBMCs 12 (4 mild, 5 severe, 3 
critical)
12 HD ↑ CD4+ CD8+ double- positive T cells
↑ naïve CD4+ T cells
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  Author Study type Patients N Control N Cells RoB
Wen et al24 Multiparametric flow 
cytometry
10 recovered (5 early 
and 5 late)
5 HD ↓ CD8+ T cells
↓ effector memory CD8+ T cell
↑CD4+ T cells, the ratio of central memory CD4+ 
T cells was significantly higher
↓ naïve CD4+ T cells, Tregs and effector memory 
CD4+ (especially in the early recovery group)
T cell expansion decreased in the early recovery 
group
High
Mazzoni et al29 Multiparametric flow 
cytometry
30 (13 severe) None ↓ CD4+ and CD8+
=TCR α/β– and γ/δ–positive T lymphocytes, across 
groups
↑ T central memory (CD45RA– CCR7+) cells
=naïve (CD45RA+ CCR7+), T effector memory 
(CD45RA– CCR7–), T effector memory CD45RA+ 
(CD45RA+ CCR7–), and HLA- DR+ cells across 
groups
↓ naïve (CD45RA+ CCR7+) and T central memory 
(CD45RA–CCR7+) cells
↑ T effector memory (CD45RA+ CCR7–) and 
senescent (CD57+) CD8+ T cells
=T effector memory (CD45RA– CCR7–) and HLA- 
DR+ CD8+ T cells across groups
↑ IL-2- producing CD4+ T cells and ↓ IL-2- producing 
CD8+ T lymphocytes and IFN-γ-producing CD4+ 
and CD8+ T cells
↓ IL-2+ IFN-γ+ TNF-α+ and IL-2+ IFN-γ+ TNF-α– 
CD8+ (polyfunctional) T cell
Unclear
Odak et al34 Multiparametric flow 
cytometry
30 (15 severe) None ↑ CD4+ effector/effector memory (CD45RA− 
CD62L−),
↓ CD4+ terminally differentiated cells (CD45RA+ 
CD62 L−)
↑ CD8 naïve T cells
↓ CD8 effector/effector memory cells, CD8 central 
memory and CD8t effector memory
↑ naïve- like γδ (γδ naïve- l) cells
↓ in effector- like γδ (γδeff- l)
High
Song et al33 Multiparametric flow 
cytometry
41 (29 mild, 12 severe) None ↑ activated CD38+ CD8+ T cells, HLA- DR+ CD8+ 
T cells and CD38+ HLA- DR+ CD8+ T cells
=CD38+ CD4+ T cells and HLA- DR+ CD4+ T cells 
among groups
High




(6 severe and 11 
mild) Convalescent 
COVID-19 (2 severe 
and 22 mild)
HD ↑ PD-1 expression in CD4 T- cell central memory 
and effector memory CD4 T cells have ↓ 
polyfunctionality for releasing both IFN-γ and TNF-α 
in vitro in acute patients effector memory and 
CD45RA+ effector CD8 T cells ↓ polyfunctionality 
for releasing both IFN-γ and TNF-α effector memory 
and CD45RA+ effector CD8 T cells ↓ for granzyme B 
and perforin
High
NK cells Mazzoni et al29 Multiparametric flow 
cytometry
30 (13 severe) None ↓ NK cells
↓ perforin and granzyme A
Unclear
Wen et al24 Multiparametric flow 
cytometry
10 recovered (5 early 
and 5 late)
5 HD ↓ NK cells High
B cells Wen et al24 Multiparametric flow 
cytometry
10 recovered (5 early 
and 5 late)
5 HD Plasma cells
↓ naïve B cells
High
Mazzoni et al29 Multiparametric flow 
cytometry
30 (13 severe) None = naive (IgD+ CD27–),memory- nonswitched (IgD+ 
CD27+), memory- switched (IgD– CD27+), and 
Blymphocytes and plasmablasts (CD27hiCD38hi)↓ 
transitional (IgMhiCD38hi) B lymphocytes
Unclear
COVID-19 severe vs healthy donors
Monocytes Lee et al25 Single cell RNA seq
PBMCs
8 COVID-19 (severe, 
mild, asymptomatic), 5 
influenza
4 HD ↑ classical monocytes
↓ DCs, non- classical monocytes, intermediate 
monocytes
IFN- I- driven signatures in addition to TNF/IL-1β-
driven inflammation
High
Silvin et al23 Cy- TOF, single cell 
RNA seq
13 COVID-19 (mild 5, 
severe 8)
25 HD ↓ non- classical CD14LowCD16High monocytes
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  Author Study type Patients N Control N Cells RoB




35 (7 moderate, 28 
severe), 7 recovered
12 HD ↓ CD4+ and CD8+
↓ CD8+ mucosal- associated invariant T cells (MAIT 
cells)
↓ innate lymphoid cells (ILCs)
=in recovered and non- recovered populations
High




35 (7 moderate, 28 
severe), 7 recovered
12 HD ↓ NK cells especially of both CD56brightCD16− and 
CD56dimCD16 populations in severe patients and ↓ 
circulating CD16+ NK cells
High
Odak et al34 Multiparametric flow 
cytometry
30 (15 severe) None ↓ NK, NKT, γδ- T cells High




35 (7 moderate, 28 
severe), 7 recovered
12 HD ↑ plasmablasts (p<0.0001)
In the non- plasmablast B cell population:
↓ CD21+ CD27+
↑ CD21− CD27− non- plasmablasts
Profound oligoclonal expansion
Same in both recovered and non- recovered patient 
populations
High
COVID-19 severe vs mild
T cells Mazzoni et al29 Multiparametric flow 
cytometry
30 (13 severe) None ↓ CD4+ without differences in subpopulation
=CD8+ total populations but ↓ T effector memory 
(CD45RA–CCR7–) and ↑ T effector memory 
CD45RA+ CCR7) cells other subpopulations =
=polyfunctional T cells
Unclear
Odak et al34 Multiparametric flow 
cytometry
30 (15 severe) None ↓ CD8+
↓Treg
↓ effector/effector memory (CD45RA− CD62L−)
High
Song et al33 Multiparametric flow 
cytometry
41 (29 mild, 12 severe) None ↓ CD4+ and CD8+ T cells
↑ PD-1+ CD8+ T cells in severe patients
↑ TIM-3+ CD8+ T cells and TIM-3+ CD4+ T cells
↑ PD-1 expression on CD38+ HLA- DR+ CD4+ T and 
CD38+ HLA- DR+ CD8+ T cells
Low
NK cells Mazzoni et al29 Multiparametric flow 
cytometry
30 (13 severe) None ↓ NK cells
↓ granzyme A
Unclear
Odak et al34 Multiparametric flow 
cytometry
30 (15 severe) None ↓ NK, NKT, γδ- T cells High
COVID-19 severe vs mild to moderate
Dendritic 
cells
Lee et al25 Single cell RNA seq
PBMCs
8 COVID-19 (severe, 
mild, asymptomatic), 5 
influenza
4 HD ↓ DCs in the severe group High




35 (7 moderate, 28 
severe), 7 recovered
12 HD ↓ conventional (CD11c+ CD123lo/−) and 
plasmacytoid (CD11c− CD123+) compared with 
moderate disease and HDs
High
COVID-19 active vs recovered
T cells Mazzoni et al29 Multiparametric flow 
cytometry
30 (13 severe) None ↓ CD4+ without differences in subpopulation
=CD8+ total populations but ↓ T effector memory 
(CD45RA–CCR7–) and ↑ T effector memory 
CD45RA+ CCR7) cells other subpop =
=polyfunctional T cells
Unclear
Odak et al34 Multiparametric flow 
cytometry
30 (15 severe) None ↓ CD8+
↓ Treg
↓ effector/effector memory (CD45RA− CD62L−)
High
NK cells Mazzoni et al29 Multiparametric flow 
cytometry
30 (13 severe) None ↓ NK cells
↓ granzyme A
Unclear
Odak et al34 Multiparametric flow 
cytometry
30 (15 severe) None ↓ NK, NKT, γδ T cells High
COVID-19 Convalescent severe vs convalescent mild
T cells Zhang et al101 Multiparametric flow 
cytometry
5 severe and 4 mild 12 HD ↑ CD8+ effector memory (TEM) cells vs HD
↓ MAIT cells
↑ CD8+ T effector memory cells re- expressing 
CD45RA (named CD8+ terminal effector cells in 
severe disease)
High
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especially in severe patients and monocytes response to 
stimulation in vitro with bacterial or viral ligand cocktail 
was impaired.23 26–28 The dendritic cells (DCs) pool was 
decreased in all patients with COVID-19 compared with 
HD27 and especially severe patients compared with both 
HD and moderate forms.25 28
Lymphoid cellular response to SAR-CoV-2 infection according 
to disease phenotype
The lymphoid compartment was also affected by 
SARS- CoV-2 infection. Lymphopenia was frequently 
reported with both CD4+ and CD8+ lymphocytes consist-
ently reduced compared with HD.26 27 29 The same results 
were observed in mild30 or severe28 versus HD and in recov-
ered patients24 versus HD. Other studies showed various 
modulation of T- cell subsets as detailed in table 2.24 31 
Blood CD8+ T cell cytotoxicity was decreased in mild30 or 
all COVID-19 patients compared with HD,32 as shown by a 
reduction in perforin, granzyme A and B production. An 
increase in PD-1 expression by CD8+ T cells was reported 
in severe patients.33 To summarise, two major abnor-
malities were described in the lymphoid compartment: 
a relative percentage increase of both central memory 
CD4+ cells and terminal effector CD8+ cells expressing 
PD1 suggesting a possible exhausted phenotype. NK cells 
were decreased in COVID-19 patients versus HD, and in 
severe COVID-19 versus both HD and mildly affected 
individuals.24 28 29 34
Finally, results regarding recovered versus active 
COVID-19 were conflicting, with one study reporting 
no differences in the lymphoid population,28 while two 
other studies showed a reduction of NK cells and of 
different T lymphocyte populations in acutely infected 
patients followed by a recovery in lymphocytes level 
during the convalescent phase.29 34 B cells were less often 
studied but an increase in circulating plasmablasts was 
reported, while other results were inconsistent.24 28 29 In 
addition, one study identified immunotypes associated 
with disease severity.35 More specifically, the Immunotype 
1 associating activated CD4 and CD8 T effector memory 
cells, along with a reduction of circulating follicular 
helper cells, hyperactivated or exhausted CD8 T cells and 
plasmablasts was associated with severe diseases, while 
Immunotype 3 lacking activated T and B cells was associ-
ated with milder forms.35
Circulating and tissue neutrophil extracellular traps during 
SARS-CoV-2 infection
Five studies assessed serum and tissue neutrophil extra-
cellular traps (NETs) release and the results are detailed 
in table 3. All of them reported an increase in circu-
lating NETs in COVID-19 regardless of disease severity, 
when compared with healthy donors or convalescent 
COVID-19 patients.36–39 Moreover, NETs levels in tracheal 
fluid were higher than plasma levels36 37 and large NETs 
infiltrating area were reported within the lung tissue 
of deceased patients, along with small vessel clot occlu-
sion with material composed of Cit- H3+ MPO+ cells 
and NETs.36 38 40 Functionally, neutrophils isolated from 
COVID- 19patients with displayed a higher baseline 
production of NETs in vitro.36 37 Circulating platelet- 
neutrophil aggregates were also observed. It has been 
suggested that they contribute to the hypercoagulability 
state observed in COVID-19 and so offer insights into the 
extensive pulmonary and systemic immunothrombosis 
that emerges in severe COVID-19.36 38
Cytokine and chemokine profiles associated with COVID-19 
severity
Studies using unbiased approaches such as mass cytom-
etry or assessing several cytokines through Multiplex or 
Luminex techniques were included. Five studies assessing 
the cytokine release in COVID-19 regardless of disease 
severity showed consistent (reported in at least two manu-
script) increase of IL-1α, IL-1β, IL- 1Ra, IL-6, IL-8, IL-10, 
IL-17, IL-18, TNF-α, IFN-α 2, IFN-γ, G- CSF, M- CSF, TRAIL, 
FGF, VEGF and PGDF when compared with HDs.26 27 41–44 
The following chemokines were also reported to be consist-
ently increased: Eotaxin, MCP3, MIP-1α. Additional 
components were reported to be increased or decreased 
only in one study and are reported in table 4. Although 
few disparities in cytokine profiles were highlighted in 
COVID-19 compared with other infections (sepsis, ARDS 
or influenza), no cytokines were consistent reported to 
be differentially expressed.27 45 Variations in cytokines 
and chemokines released were also reported; depending 
on disease severity when comparing mild with moderate 
disease,27 42 mild or moderate vs severe.26 27 41 42 46 Of 
interest, patients with severe COVID-19 displayed higher 
levels of IFN-γ, IL- 1RA, IL-6, IL-10, M- CSF, MCP-1, MCP-3 
and ENRAGE when compared with milder forms.26 27 42 46 
  Author Study type Patients N Control N Cells RoB
  Mathew et al35 Multiparametric flow 
cytometry
125 hospitalised, 36 
recovered
60 HD Immunotype 1: Activated CD4 and CD8 T effector 
memory cells, ↓ circulating follicular helper cells, 
hyperactivated or exhausted CD8 T cells and 
plasmablasts Positively correlated with disease 
severity
Immunotype 2: Not correlated with disease severity
Immunotype 3: No activated T or B cells. Negatively 
correlated with disease severity.
  
ATL, Atlanta; CITE- seq, Cellular Indexing of Transcriptomes and Epitopes by Sequencing; CyTOF, cytometry by time of flight; gMDSC, granulocytic myeloid derived suppressor cells; 
HD, healthy donor; HK, Hong- Kong; HLA- DR, Human Leucocyte Antigen – DR isotype; IFN, interferon; IL, interleukine; ITGAM, integrin alpha M; LDN, low density neutrophils; mTOR, 
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In addition, one study showed that IL-1α, IL-1β, IL- 17A, 
IL-12 p70 and IFN-α were decreasing steadily after 10 
days in patients with moderate forms of COVID-19, while 
severe patients maintained higher levels.26 Del Valle et al 
have also shown that high serum IL-6 and TNF-α levels at 
the time of hospitalisation were strong and independent 
predictors of patient survival (p<0.0001 and p=0.0140, 
respectively), adjusted on prognostic factors in a large 
cohort of patients.47
Interferon response to SARS-CoV-2 infection at the 
transcriptional and protein level
Three studies explored IFN response in patients with 
COVID-19 using CyTOF48 or multiparametric flow cytom-
etry32 (table 5). Of interest, type I IFN responses were 
not sustained over time in severe and critical patients.32 
In one study, plasma levels of IFN-α2 protein and IFN 
activity were significantly reduced in severe and critical 
patients compared with patients with mild- to- moderate 
disease.48 In another study, impaired mechanistic target 
of rapamycin (mTOR) signalling and IFN-α production 
by plasmacytoid DCs was shown, and single- cell RNA 
sequencing revealed a lack of type I IFNs in patients 
with severe COVID-19 and transient expression of IFN- 
stimulated genes.32 The failure to maintain high IFN 
production in severe forms of COVID-19 could also be 
related to loss- of- function mutations in the interferon 
pathway49 and/or the presence of anti- IFN antibodies 
associated with more severe forms of the disease.13 
Noting the aforementioned loss of function in IFN 
pathways, the data were contradictory regarding IFN 
production by monocytes, while an IFN signature was 
reported in classical inflammatory monocytes in one 
study, a reduction of IFN production was reported in 
another study.22 25 Similarly, IFN-α and IFN-β production 
in response to stimulation in vitro were impaired in acute 
COVID-19 patients’ DCs, while in convalescent patients, 
DCs could only produce IFN-β. Conversely, serum levels 
of IFN-α and IFN-γ were increased in another study, 
and a correlation between viral load and IFN levels was 
reported.26 However, methods used for cytokines meas-
urement (Simoa or Luminex) and timing of samples 
(early vs late timepoints) were different between studies. 
In addition, cytokines were assessed at both transcrip-
tional or protein levels depending on the study and this 
could partly explain the observed differences.
Humoral immune response to SAR-CoV-2 infection according 
to disease phenotype
Five longitudinal studies assessing anti- SARS CoV-2 
IgM and IgG using commercially available assays were 
included (table 6).50–54 Three studies used ELISA,50 51 53 
while two studies used chemiluminescence immunoassays 
(CLIA)52 targeting various SARS- CoV-2 antigens. A vari-
able timing of appearance for IgM within the first 2 weeks 
after symptom onset has been described and one study 
reported that patients with mild COVID-19 did not show 
any IgM response up to 4 weeks after symptom onset.50 
As far as IgGs are concerned, studies using ELISA agreed 
that these antibodies appear by the second/third week 
Table 3 Circulating and tissue neutrophil extracellular traps (NETs) during SARS- CoV-2 infection
Author Patients N Control   RoB
Middleton et al36 33 COVID-19 
(n=28 hospitalised, 
n=5 convalescent)
17 HD ↑ circulating NETs (MPO- DNA complexes) in patients vs HD and 
convalescent.
NET levels in tracheal aspirate fluid>in plasma samples
Plasma NETs levels=in HD and recovered patients
↑ baseline NETs levels in PMNs isolated from COVID-19 patients
↓ in PMN granularity vs HD
↑ circulating platelet- neutrophil aggregates
High
Veras et al37 32 COVID-19 (17 
critical and 15 
severe)
19 HD ↑ circulating nets
↑ NETs in the tracheal aspirate from COVID-19 patients
NET levels in tracheal aspirate fluid>in plasma samples
↑ baseline NET levels in PMNs isolated from COVID-19 patients
↑ branch lengths of the released NETs
Unclear
Zuo et al39 51 COVID-19
(27 severe, 24 
mild)
30 HD ↑ cell- free DNA, MPO- DNA complexes, citrullinated histone H3
COVID-19 sera trigger control neutrophils to release NETs
High
Leppkes et al38 71 COVID-19 None ↑ PMNs with low buoyant density, activation pattern (low 
L- selectin, CD62L) and partial degranulation (increased 
CEACAM-8, CD66b) resembling low- density granulocytes.
↑ circulating platelet- neutrophil aggregates
Exhausted phenotype with ↓ spontaneous oxidative burst
↑ MPO- DNA complexes and NE- DNA complexes
↑ NE activity in the blood more than 30- fold and 60- fold
High
DNA, desoxyribonucleic acid; HD, healthy donor; MPO, myeloperoxidase; NE, neutrophil elastase; NETs, neutrophil extracellular traps; 
PMNs, polymorphonuclear neutrophils.
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Table 4 Cytokine and chemokine profiles associated with COVID-19 severity
  Author Technique Patients N Control N Cytokines RoB
COVID-19 (mild, 
moderate and/
or severe) vs 
control





8 severe, 4 
convalescent)
4 HC ↑ IL-1β, IL- 1Ra, IL-2, IL- 2Ra, IL-6, IL-7, IL-
8, IL-9, IL-10, IL-1, IL-15, IL-17, IL-18
↑ TNF-α, IFN-α2, IFN-γ, G- CSF, M- CSF, 
TRAIL, FGF, PGDF, Eotaxin, CXCL1/GRO-α
↑ MCP3, MIP-1α, MIG, MCP-1
High
Xu et al43 Multiplex (48 
cytokines)
(7 mild, 6 severe, 10 
fatal)
4 HD ↑ 20 cytokines, chemokines and growth 
factors, including IL-1α, IL-1β, IL-4, IL-5, 
IL-7, IL-12 p40, IL-13, IL-16, TNF-α, TRAIL, 
IFN-α2, CXCL1/GRO-α, CXCL12/SDF-1α, 
CCL11/Eotaxin, CCL27/CTACK, G- CSF, LIF, 
MIF, SCGF and VEGF
High
Fraser et al41 Multiplex (57 
cytokines)
10 severe 10 HD ↑ elastase 2, HSP-70, IL- 1RA, IL-6, IL-8, ↑ 
MCP-1 monokine induced by γ-IFN, MMP8.
↑ resistin, TNF, IL-10, IL-18, M- CSF, 
granzyme B, thrombospondin-1, MIP-1β, 
MMP-2













↑ IL-6, MCP-3, TNFα, EN- RAGE, TNFSF14 
and Oncostatin M
High
Lucas et al26 Multiparametric 
flow cytometry
113 (moderate 80, 
severe 33)
108 HD ↑ IL-1α, IL-1β, IL- 17A, IL-12 p70 and IFN-α Low
COVID-19 vs 
other diseases
Wilson et al45 Luminex
(76 cytokines)
15 (9 critical) vs 16 
critical sepsis and 12 
critical ARDS
None ↑ thymic stromal lymphopoietin lower in 
moderate and severe COVID-19 compared 
with ARDS and sepsis
IL-16 lower in moderate COVID-19 


















Sims et al44 Multiplex (184 
cytokines)+ IL-19 
assay
25 (6 mild, 4 
moderate,8 severe, 7 
critical)
20 HD ↑ 21- fold IFN-γ, 18- fold IL-6, IL-10, MCP-1, 
MCP-2, 12- fold MCP-3, 10- fold CXCL10, 
2- fold MCP-3 IL-19 (p<0.001)
High
Lucas et al26 Multiparametric 
flow cytometry
113 (moderate 80, 
severe 33)
108 HD IL-1α, IL-1β, IL-6, IL-10, IL-18 and TNF-α 
are correlated with severity
Low
  Del Vallee et al47 ELISA 1484 HD
CAR T- cell 
treated patients 
with or without 
cytokine release 
syndrome
↑ IL-6 (mean 332 pg/mL) (p < 0.0001), IL-8 
((mean 110 pg/mL) (p<0.0001) and TNF-α 
(mean 28 pg/mL) (p<0.0001)




Chi et al42 Multiplex (48 
cytokines)
70
(22 mild, 36 
moderate
8 severe, 4 
convalescent)
4 HD ↑ IL-6, IL-7, IL-10, G- CSF, M- CSF
IP-10, MCP-3, MIP-1α, MIG, MCP-1
High
Sims et al44 Multiplex (184 
cytokines)+ IL-19 
assay
25 (6 mild, 4 
moderate,8 severe, 7 
critical)
20 HD ↑ IFN-γ, IL- 1RA, IL-6, IL-10, IL-19, MC-
1, MCP-2, MCP-3, CXCL9, CXCL10, 
CXCL5, EN- RAGE, and poly(ADP- ribose) 
polymerase 1 (p<0.001)
High
Xu et al43 Multiplex (48 
cytokines)
(7 mild, 6 severe, 10 
fatal)
4 HD ↑ 16 cytokines, chemokines and growth 
factors, including HGF, CXCL8/IL-8, CCL7/
MCP-3, CCL2/MCP-1, CXCL9/MIG, 
CXCL10/IP-10, IL-6, IL-18, IL-2, MCSF, 
IL- 1Rα, IL- 2Rα/CD25, IFN-γ, CCL3/MIP-
1α, basic FGF and SCF were significantly 
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after symptom onset while those using CLIA identified 
IgGs as early as week 1.52 54 IgGs were still detectable 
up to 6–8 weeks after symptom onset.50 52–54 The studies 
assessing neutralising antibodies (Nab) provided highly 
heterogeneous data and since assays were not standard-
ised, comparison across studies was not possible.50 55–57 
The SLR did not retrieve any article identifying a role 
of antibody dependent enhancement and detrimental 
effect of anti- SARS- CoV-2 antibodies.
Platelets, endothelial dysfunction and thrombosis and SARS-
CoV-2 infection
A clear pathophysiological link between lung inflamma-
tion in COVID-19 and extensive immunothrombosis that 
has been associated with severe disease and mortality 
exists pointing towards potential involvement of plate-
lets and endothelial cells. One study sequenced total 
RNA from platelets isolated from SARS- CoV-2 infected 
individuals identifying specific clusters of expression in 
  Author Technique Patients N Control N Cytokines RoB
Lucas et al26 Multiparametric 
flow cytometry
113 (moderate 80, 
severe 33)
108 HD ↑ thrombopoietin, IL-33, IL-16, IL-21, IL-23, 




Chi et al42 Multiplex (48 
cytokines)
70
(22 mild, 36 
moderate,
eight severe, 4 
convalescent)















Chi et al42 Luminex 70
(22 mild, 36 
moderate
eight severe, 4 
convalescent)
4 HD ↑ MCP-3, MIG and MIP-1α High
Wilson et al45 Luminex
(76 cytokines)
15 (9 critical) vs 16 
critical sepsis and 12 
critical ARDS
None ↑ PDGF- BB High
Wilson et al45 Luminex
(76 cytokines)
15 (9 critical) vs 16 
critical SEPSIS and 
12 critical ARDS
None No difference between four groups in IL-1β, 













↑ IL-6, oncostatin M High
Lucas et al26 Multiparametric 
flow cytometry
113 (moderate 80, 
severe 33)
108 HD After day 10, the following markers 
declined: IL-1α, IL-1β, IL- 17A, IL-12 p70 
and IFN-α in patients with moderate 
disease, while patients with severe 
COVID-19 maintained elevated levels
Following day 10, IFNα, IFNλ, IL-1β, IL- 1Ra, 
IL-18, IL-33, Eotaxin-2 remained high in 




Xu et al43 Multiplex (48 
cytokines)
(7 mild, 6 severe, 10 
fatal)
4 HD ↑ 16 cytokines, chemokines and growth 
factors, including HGF, CXCL8/IL-8, CCL7/
MCP-3, CCL2/MCP-1, CXCL9/MIG, 
CXCL10/IP-10, IL-6, IL-18, IL-2, MCSF, 
IL- 1Rα, IL- 2Rα/CD25, IFN-γ, CCL3/MIP-1α, 
basic FGF and SCF
Among these IFN-γ, IL- 1Rα, IL-2, IL- 2Rα, 
IL-6, CXCL8, IL18, CCL2, CCL3, SCF, 
HGF and basic FGF were upregulated to 
similar levels at the early stages and then 
upregulated significantly in fatal patients at 
day 14
High
ARDS, acute respiratory distress syndrome; CCL, C- C motif chemokine ligand; CEACAM-8, CEA cell adhesion molecule; CXCL, chemokine (C- X- C motif) 
ligand; FGF, fibroblast growth factor; G- CSF, granulocyte colony- stimulating factor; HGF, Hepatocyte Growth Factor; HSP, heat shock protein; IFN, interferon; 
IL, interleukine; IP-10, interferon gamma- induced protein 10; LIF, leukaemia inhibitory factor; MCP, monocyte chemotactic protein; M- CSF, macrophage colony 
stimulating factor; MIF, macrophage migration inhibitory factor; MIG, monokine induced by gamma- interferon; MIP, monocyte chemotactic protein; MMP-2, matrix 
metalloproteinase; PDGF- BB, platelet- derived growth factor; SCF, stem cell factor; SCGFB, stem cell growth factor beta; SDF-1α, stromal cell- derived factor 1; 
CAR T- cell, chimeric antigen receptor T cells; TNF, tumour necrosis factor; TNFSF14, tumour necrosis factor ligand superfamily member 14; TRAIL, tumour necrosis 
factor–related apoptosis–inducing ligand; VEGF, vascular endothelial growth factor.
Table 4 Continued
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patients with COVID-19, regardless of severity, compared 
with normal subjects. In particular, enriched pathways 
observed in COVID-19 associated with protein ubiq-
uitination, antigen presentation and mitochondrial 
dysfunction. Of interest, one of the top significantly over-
expressed genes was IFITM3, whose variants have been 
associated with disease severity as mentioned above.11 In 
addition, a comparison of data obtained in patients with 
COVID-19 with existing RNA- Seq data in H1N1 influ-
enza and sepsis revealed that numerous gene changes 
were unique for each disease condition. Of the differen-
tially expressed genes that were shared, >96% changed 
in the same direction.58 Data regarding the detection 
of platelets positive for SARS- CoV-2 RNA revealed that 
they were present only in a small subset of patients with 
COVID-19.59 60 With regard to platelet function, two 
studies showed higher basal activation in COVID-19 as 
demonstrated by P- selectin expression, compared with 
normal subjects,58 59 with basal hyperactivation and stim-
ulated in vitro responses being more pronounced in 
severe COVID-19.58 59 Since P- selectin is also responsible 
for interaction between platelets and monocytes, it is not 
surprising that Hottz et al also demonstrated that platelets 
form higher numbers of aggregates with monocytes in 
severe COVID-19. In addition, while aggregated, platelets 
induce monocyte expression of tissue factor (TF) via P- se-
lecting and integrin αIIb/β3.59 Finally, while data on in 
vitro platelet aggregation are conflicting,58 61 two studies 
agreed on a greater adhesion and spreading on fibrin-
ogen and collagen compared with normal subjects58 and 
in severe vs mild COVID-19.60
Regarding circulating endothelial cells (CECs), a 
marker of endothelial injury, data are conflicting with 
two studies reporting increased numbers in COVID-19 vs 
normal subjects,62 63 one study reported numbers similar 
to those of normal controls64 and one study observed 
higher numbers of CECs in patients with COVID-19 in 
intensive care unit (ICU) versus those not admitted to 
ICU.65 Only one study investigated circulating endo-
thelial progenitors (CEPs) and observed that they were 
higher in COVID-19 compared with normal subjects but 
there was no difference between mild and severe disease. 
Of interest, apoptotic CEPs/mL positively correlated 
with the copies of SARS‐CoV‐2 RNA in severe COVID-
19.64 All data pertaining to these research questions are 
presented in table 7.
Table 5 Interferon response to SARS- CoV-2 infection







50 (15 mild to 
moderate, 17 
severe and 18 
critical patients
HD 18 COVID-19 (mild, 
moderate and/or 
severe) vs HD





↑genes involved in 
type I IFN signalling 
(such as IFNAR1, 
JAK1 and TYK2)
↓ IFN- stimulated 




↓↓ plasma levels of 
IFN-α2 protein and IFN 
activity significantly
Lower type I IFN 
response in severe vs 
critical patients
Zhu et al46 Multiparametric flow 
cytometry
Patients’ DC cultures
Acute COVID-19 (6 
severe and 11 mild)
Convalescent 
COVID-19 (2 severe 
and 22 mild)





IFN-α was not induced 
in 3/3 active patients 
and 3/4 convalescent 
patients
IFN-β was not 
increased in 3/3 active 
patients, rather only 
slightly elevated in 3/4 
convalescent patients 
indicating a reduced 
capacity of making 
antiviral interferon
High
HD, healthy donor; IFN, interferon; JAK, Janus kinase; MCP, monocyte chemoattractant protein; TYK, tyrosine kinase.
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Multiparametric algorithms for prediction of disease outcome 
and progression
Several algorithms have been published, using mostly a 
retrospective design on both inception and validation 
cohorts (table 8). Most algorithms included clinical 
parameters such as: demographics (age, race, ethnicity, 
gender, socioeconomic status, smoking, body mass 
index), symptoms (fever, fatigue, shortness of breath, 
diarrhoea, vomiting, haemoptysis, dyspnoea, uncon-
sciousness), comorbidities (asthma, diabetes, hyper-
tension, immunosuppressive disease, cancer history) 
and treatment (nonsteroidal anti- inflammatory drugs, 
immunomodulatory therapies). Biological parameters 
were also included as follows: immune cells (white cell 
count, neutrophil count, lymphocyte count, neutrophil- 
to- lymphocyte ratio), inflammatory markers (C reactive 
protein, ferritin), coagulation markers (platelets, procal-
citonin, NT- proBNP, AT) and others (haemoglobin, 
ALT, AST, direct bilirubin, albumin, chloride, potas-
sium, anion gap, glomerular filtration rate, blood urea 
nitrogen, myoglobin, troponin, lactate dehydrogenase). 
Imaging parameters including severe chest X- ray radio-
graphic abnormalities and diffuse pulmonary infiltration 
on CT that have also been linked to severe disease.
One multiparametric model aimed at predicting the 
risk of hospitalisation with an area under the curve (AUC) 
of 0.9,66 while three studies aimed at predicting survival 
with AUC between 0.879 and 0.955,67–69 and two other 
aimed at predicting disease mortality with AUC between 
0.871 and 0.975.70 71 Other algorithms were developed, 
aiming at predicting disease progression towards a severe 
phenotype with AUC from 0.77 to 0.9.72–79 Each algo-
rithm is detailed in table 8.
Difference in pathogenesis of SARS-CoV-2 infection between 
adults and children
Very few studies compared adult and paediatric patients 
with SARS- CoV-2 infection and all of them evaluated 
very small cohorts. Some differences were observed with 
regard to clinical (eg, diarrhoea and vomiting more 
frequent in children) and haematological (eg, neutro-
penia more frequent in children) features. This may hint 
possible different pathogenic mechanisms in response 
to SARS- CoV-2 infection; none of the studies specifically 
explored them.80–82
Gut and SARS-CoV-2 infection
Only four publications about two studies investigating 
the gut microbiome of patients with COVID-19 were 
retrieved by the SLR and both of them identified a dysbi-
osis (online supplemental table S3). A highly heteroge-
neous configuration that was different according to the 
faecal SARS- CoV-2 viral load was observed, along with 
depletion of beneficial commensals and abundance of 
Table 6 Humoral immune response to SAR- CoV-2 infection according to disease phenotype








ELISA* ↑ at D10–15 after 
onset
Remained ↑ for at 
least for 6W
HD: no Abs detected
SEVERE: ↑ within 
W1-2 and ↓ after W4
MILD: Most patients 
negative up to W4
HD: no Abs detected
ND  ► 73.9% of 
patients 
generated NAb
 ► Higher NAb 








ELISA† ↑ at D11-12 after 
onset
Remained ↑ for ≥30
HD: 5% positivity
↑ at D9 after onset,
Remained ↑ for ≥30D
HD: No Abs
ND ND Unclear
Zhao et al51 173
COVID-19
ELISA‡ ↑ at D14 (median) ↑ at D12 (median) ND ND Unclear
Xie et al52 56 COVID-19 CLIA§ ↑ in W1
Remained ↑ for at 
least 41D, even after 
the resolution of 
infection
↑ in W1 and ↓ at 
W4-5
ND ND Unclear
Zhou et al54 52 COVID-19 CLIA* ↑ in W1
100% patients 
positive at D28
Remained ↑ up to 
D54
↑ in W1 and peak at 




‡IgM: receptor binding domain of the spike protein; IgG: a recombinant nucleoprotein.
§Envelope (E) protein and nucleocapsid (N) protein.
D, day; HD, healthy donor; M, month; NAb, neutralising antibodies; ND, not detailed; RoB, risk of bias; W, week.
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Table 7 Endothelial dysfunction, thrombosis and SARS- CoV-2 infection
Author Methods Population Description of result Rob
Platelet gene expression
Manne et al58 RNA Seq 10 COVID-19
vs
5 HD
 ► Non- ICU and ICU COVID-19 patients clustered together, but 
separately from healthy controls
 ► In COVID-19 enriched pathways associated with protein 
ubiquitination, antigen presentation and mitochondrial dysfunction
 ► One of the top significantly overexpressed genes in COVID-19 is 
IFITM3, coding for an antiviral protein normally absent in HD and 
overexpressed in dengue and H1N1
 ► No expression of ACE2 mRNA in COVID-19 and HD (nor of ACE2 
protein by WB)
 ► In 2 ICU COVID-19 mRNA expression of the SARS- CoV-2 N1 was 
detected
 ► A comparison with existing RNA- Seq data in H1N1 and sepsis 
revealed that numerous gene expression differences between both 
condition. Of the shared gene expression,>96% changed in the 
same direction.
Low
Zaid et al60 PCR 49 COVID-19
vs
17 HD
SARS- CoV-2 RNA was detected in 11 COVID-19 (9/38 mild and 2/11 
severe) and in no HD. Individuals with positive platelets for SARS- 









 ► Higher basal expression of P- sel vs HD
 ► Increasing doses of 2MeSADP and PAR1 peptide (SFLLRN or 
TRAP) induced significantly greater activation (P- sel expression) vs 
HD
 ► P- sel expression in response to low- dose 2MeSADP significantly 
correlated with COVID-19 severity based on SOFA scores
 ► 2MeSADP, SFLLRN (TRAP) and collagen- related peptide resulted in 
decreased PAC-1 binding vs HD (not due to altered expression of 
αIIb which was similar in the 2 groups)
Low





 ► Higher basal expression of P- sel vs HD
 ► Higher basal expression of P- sel in severe vs mild/asymptomatic 
COVID-19
 ► Similar expression of P- sel in mild/asymptomatic vs HD
 ► TXA2 synthesis was increased in platelets from severe but not mild/
asymptomatic COVID-19
 ► Platelet- derived factors are present in tracheal aspirates from 
COVID-19 patients
 ► P- selectin elevations above HD median was predictive of in- 
hospital mortality (OR=9.6 (95% CI 1.02 to 90.35); p=0.045).
Low
Zaid et al60 PCR 49 COVID-19
vs
17 HD
Suboptimal concentrations of α-thrombin induced higher expression 









 ► In vitro platelet aggregation in response to low- dose agonists 
(2MeSADP, thrombin and collagen) was significantly increased vs 
HD
 ► Aggregation was more pronounced in ICU COVID-19, especially at 
lower doses of thrombin
 ► Aggregation is associated with increased MAPK pathway in ICU 
COVID-19
 ► PLA2 in upregulated at baseline vs HD and further increases on 
stimulation with low- dose agonists
 ► TXA2 was increases by 2MeSADP in platelets from COVID-19 ICU
 ► In vitro aggregation of platelets from COVID-19 ICU could be 
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Author Methods Population Description of result Rob





 ► In vitro generation of procoagulant platelets in response to dual 
agonist stimulation with thrombin and convulxin was significantly 
lower vs HD
 ► Procoagulant platelet responses were similarly reduced in non- ICU 
and ICU COVID-19
 ► Dysregulated procoagulant platelet responses in COVID‐19 are due 
to higher mitochondrial ROS levels at baseline and dual agonist 
stimulation of platelets from COVID‐19 patients did not elicit further 
increases in mitochondrial ROS generation
 ► In vitro generation of procoagulant platelets in response to agonist 
stimulation with Ca2+ ionophore A23187 was similar to HD
Unclear
Platelets adhesion




Greater adhesion and spreading on fibrinogen and collagen vs HD Low
Zaid et al60 PCR 49 COVID-19
vs 17 HD
The number of adherent platelets on a collagen- coated surface under 
flow conditions was significantly higher in severe vs mild
Unclear
Platelets and monocytes interactions





 ► Platelets formed higher numbers of aggregates with monocytes in 
severe COVID-19
 ► While aggregated, platelets induced monocyte expression of tissue 
factor (TF) via P- sel and integrin αIIb/β3 and TF expression was 
maximal at 2 hour of interaction
 ► Only P- selectin, but not αIIb/β3, neutralisation was able to reduce 
platelet- monocyte aggregate formation
 ► Abciximab pre- treatment did not affect P- sel expression on 
platelets from COVID-19 patients that were aggregated with 
monocytes
 ► Aspirin or clopidogrel failed to modify platelet- monocyte aggregate 
formation or platelet- induced TF expression
 ► TF expression in monocytes was increased among non- survivors
 ► Platelet- monocyte aggregates did not associate with mortality
Low
Circulating endothelial cells







 ► CECs/mL were similar to HD
 ► Less apoptotic CECs/mL vs HD
 ► Less apoptotic CECs/mL in recovered COVID-19 vs HD, vs mild 
COVID-19 vs severe COVID-19
 ► Apoptotic CECs/mL inversely correlated with viral RNA copies
Unclear





 ► CECs/mL higher vs HD
 ► CECs/mL higher in early phase of disease
High
Guervilly et al65 Immuno 
magnetic 
separation




 ► CECs/mL higher in ICU vs non- ICU COVID-19 independently of all 
comorbidities
 ► CECs/mL directly correlated with length of hospital stay
 ► CECs/mL independently associated with CKD
Unclear




vs 30 clinically 
suspected non 
COVID-19
 ► CECs/mL higher vs HD
 ► CECs/mL lower in COVID-19 treated with anticoagulation (for any 
reason) vs untreated
 ► In patients treated with ACEi or ARBs the effect of curative 
anticoagulation on the CEC level was more pronounced
Unclear
Circulating precursors endothelial cells







 ► Viable and apoptotic CEPs/ml higher in acute and recovered 
COVID-19 vs HD
 ► No difference between mild and severe COVID-19
 ► Apoptotic CEPs/ml positively correlated with the copies of SARS- 
CoV-2 RNA in severe COVID-19
Unclear
HD, healthy donor; ICU, intensive care unit; RoB, risk of bias.
Table 7 Continued
 on F
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Table 8 Multiparametric algorithms for prediction of disease outcome and progression
Author Design
Statistical 









Age, race, ethnicity, gender, 
smoking, BMI, socioeconomic 
status, fever, fatigue, shortness 
of breath, diarrhoea, vomiting, 
asthma, diabetes, hypertension, 
immunosuppressive disease, 
NSAIDs, immunosuppressive 
treatment, platelets, AST, 





Scaled Brier Score 















Neutrophil count, lymphocyte 













Hypertension, higher neutrophil- 











Age, lactate dehydrogenase 
level, neutrophil- to- lymphocyte 
ratio and direct bilirubin level

























Age, neutrophil- to- lymphocyte 


















Obesity, gender, haemoglobin, 
lymphocyte, and the cDIC- 
ISTH (International Society on 
Thrombosis and Haemostasis 
score for compensated 
disseminated intravascular 
coagulation score) including 
platelet count, prothrombin 














Age, obesity, body temperature, 
respiratory rate, lymphocyte 
count, creatinine≥1 mg/dL, C 
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opportunistic pathogens. Of interest, these abnormal-
ities persisted even after recovery from COVID-19.83–86 
In addition, when comparing the gut microbiome of 
patients with COVID-19 with that of patients with H1N1 
influenza, differing overall compositions were observed. 
Opportunistic pathogens were reported in with more 
pronounced abundance in COVID-19.84 Interestingly, a 
specific set of bacterial species allowed to discriminate 
the two patient groups.86 One study identified increased 
levels of biomarkers of gut leakage and gut homing, 
while no difference in biomarkers of enterocyte damage 
were observed in patients with COVID-19 compared with 
normal subjects.87
Histological lesions related to SARS-CoV-2 infections
Most histological studies have assessed lung tissue 
damage linked to COVID-19 in deceased individuals 
(online supplemental table S4). Two studies reported 
viral inclusions assessed by electronic microscopy immu-
nohistochemistry with or without in situ hybridisa-
tion.4 40 Viral inclusions were observed mainly in airways 
and tracheal epithelium and pneumocytes. Histological 
studies of autopsy specimens from patients with identi-
fied cause of death being various among which ARDS, 
consistently reported the following tissular lesions: 
exudative, proliferative, mixed, organising or fibrosing 
diffuse alveolar damage (DAD); associated with micro-
vascular and macrovascular thrombi.4 88 89 Of interest in 
the study from Li et al, patients with fibrosing DAD were 
younger (p=0.034) and had a longer duration of illness 
(p=0.033), hospitalisation (p=0.037) and mechanical 
ventilation (p=0.014) compared with those with acute 
DAD. Similarly, patients displaying organising DAD 
Author Design
Statistical 
model Population Score components
Diagnostic 
performances RoB



































Age, comorbid diseases, 
neutrophil‐to‐lymphocyte ratio, 


















HNC- LL (hypertension, 
neutrophil count, C reactive 







V Validation No 2: 
AUC=0.826, p<0.001
Unsure





Age, white cell count, neutrophil, 















Chest radiographic abnormality, 
age, hemoptysis, dyspnoea, 
unconsciousness, number of 
comorbidities, cancer history, 
neutrophil- to- lymphocyte ratio, 








AUC, area under the curve; RoB, risk of bias.
Table 8 Continued
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features had a longer duration of illness (p=0.032) and 
hospitalisation (p=0.023) compared with those with 
acute DAD.89 De Michele et al90 have identified different 
histological patterns associated with COVID-19 severity. 
In their autopsy series, 29 (73%) of 40 patients presented 
with acute lung injury (ALI) defined by the presence of 
hyaline membranes, DAD—with or without—an organ-
ising (proliferative) phase. This pattern was associated 
with longer hospitalisation (p=0.02), longer ventilation 
(p=0.003) and more radiographic alveolar infiltrates 
(p=0.01).
Comorbidities and immune response to SARS-CoV-2 infection
Although many studies assessed the impact of comor-
bidities on clinical outcomes of COVID-19,91 only one 
study explored the effect of comorbidities, namely, type 
2 diabetes (T2D) on immune response in patients with 
COVID-19 (online supplemental table S5). By means of 
unsupervised analyses of cytometry data and principal 
component analysis) including lymphocyte and mono-
cyte subpopulations, the authors identified three distinct 
clusters of patients corresponding to COVID-19 without 
T2D, COVID-19+T2D and T2D without COVID-19‐19. In 
more detail, an increase of CD14+ monocytes, increased 
phenotypically switched monocytes and decreased clas-
sical monocytes were observed in in patients with COVID-
19+T2D compared with those with COVID-19 without 
T2D.92
Immunosenescence and SARS-CoV-2 infection
Three studies assessed the impact of immunosenes-
cence on immune response to SARS- CoV-2 infection 
using different age cut- offs.30 93 94 Among other, CD4+ 
and CD8+ T cells were reduced compared with younger 
patients, and CD8+ T cell cytotoxicity was reduced as 
demonstrated by a decrease in granzyme and perforin 
expression. Two studies reported that CD8+ T cells 
displayed an exhausted phenotype as shown by higher 
PD-1 expression.93 94 However, it is worth noting that PD-1 
is known to be increased in older patients regardless of 
their SARS- CoV-2 infection status.95 Other cell popula-
tion are reported in only one study, and the results are 
detailed in online supplemental table S6.
Consequences of immunomodulatory drugs on viral load and 
host antiviral immune response
Only a few studies assessed the effects of immunomod-
ulatory drugs on viral load and host antiviral immune 
response (online supplemental table S7). Several 
cytokines levels, including ↓ IL-6, MCP-3 and IFN-γ were 
reduced after baricitinib treatment in four patients.44 
After tocilizumab treatment, two studies reported an 
increase in lymphocyte counts in small groups of five 
patients.29 96 This is in line with data from clinical trials.97 
In addition, the administration of Tocilizumab restored 
of NK cell cytotoxicity29 and rescued HLA- DR expression 
in conventional monocytes.96
DISCUSSION
This SLR summarises current evidence on SARS- CoV-2 
infection pathogenesis as viewed from the Rheuma-
tology perspective. We gathered a large amount of 
publications showing how SARS- CoV-2 infection affects 
immune and non- immune cells. While some features 
were consistently reported across studies for both the 
lymphoid and the myeloid compartment, the hetero-
geneity of results prevented any firm conclusion being 
drawn in many publications. We did not retrieve data on 
mast cell and eosinophils since studies remain scarce.98 
From a cytokines’ point of view, IL-6, TNFα and IL-1β 
production and release were associated with COVID-19 
severity.99 It is noteworthy that the elevations in cytokine 
levels including IL-6 were reported to be mild or modest 
in general compared with sepsis, or oncoimmunotherapy- 
related cytokine storm and MAS.6
In addition, genetic predisposition, especially linked 
to the type I IFN pathway, was shown to be responsible 
for more severe phenotypes in different cohorts, high-
lighting molecules and pathways deemed essential for a 
functional anti- SARS- CoV-2 response. Despite the clear 
genetic evidence incriminating loss- of- function muta-
tions in the IFN pathway and the strong history of IFN 
link to viral immunity, a clear beneficial role of type I IFN 
cannot be determined so far and may vary depending on 
the timing and the stage of the disease. In fact, type I 
IFN response appeared to be variably described across 
studies, probably because of variable methods (tran-
scriptomic data vs protein measurements) and timing 
of analysis. It is very likely that, while IFN response is 
initiated in all patients with COVID-19, the magnitude 
of IFN production and its duration to clear the virus 
may differ according to disease severity, and it probably 
fails to remain high in severe and critical patients, there-
fore contributing to impaired viral response and worse 
outcome. Longitudinal studies measuring IFN response 
across time and disease severity are warranted to confirm 
this hypothesis. In addition, IFN protein measurement in 
blood may not reflect disease in tissue.
Humoral response to SARS- CoV-2 tended to be vari-
able among individuals and the presence of IgM was 
inconsistently reported, suggesting that some individuals 
do not develop an IgM response. Non- immune cells such 
as platelets and endothelial cells exhibit an activated 
phenotype favouring clotting along with a hypercoagu-
lability state. Of interest, children and young adults were 
displaying different features compared with infected 
adults, presenting with extremely common mild forms of 
the disease and more rarely severe disease termed multi-
system inflammatory syndrome in children. All these 
findings taken together address partly the knowledge gap 
in understanding SARS- CoV-2 infection mechanisms.
While conducting this SLR, we were faced with several 
limitations that prevented from drawing conclusions 
in several aspects of disease pathogenesis. First, limita-
tions related to study design itself or methods used since 
most studies were assessing only a few randomly selected 
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cytokines or cell subsets. Such approaches are biased and 
could potentially lead to inaccurate or non- generalisable 
results. In this SLR, we included only studies using unsu-
pervised clustering approaches through single cell RNA 
seq or similar techniques; or at least multiparametric 
flow cytometry for cell assessment. Similarly, only mass 
spectrometry or multiplexed cytokine assays that could 
simultaneously assess several cytokines (eg, Luminex, 
Muliplex) were included and analysed. Through this strict 
approach, we aimed at reducing the risk of biased results. 
The second type of limitations pertained to the hetero-
geneity of inclusion criteria and treatments received by 
individuals included in the studies. In fact, the definition 
of disease severity was extremely variable across studies, 
since the WHO scale was not always used, and also two 
WHO scales exist, classifying patient of moderate severity 
differently.100
In addition, in several studies, patients who were 
enrolled could receive several treatments including 
immunomodulators such as steroids or IL-6 receptor 
antagonists; and the results were presented without clus-
tering or subgroup analysis, hereby leading to high risk 
of results’ misinterpretation. Another aspect pertains to 
multiparametric algorithm studies, where in addition of 
the very common retrospective design, most of the algo-
rithms published were not validated in other cohorts, 
while those who did, were in fact validated in temporally 
different cohorts but in the same population. Although 
the current context of the pandemic and associated rush 
in delivering useful science to better understand and 
treat the disease might explain some of these issues, the 
interpretation of the results needs to be guarded.
In conclusion, the results of the present SLR highlight 
the aberrant immune and non- immune cellular response 
to SARS- CoV-2 infection. Despite the massive amount of 
literature published, the knowledge gap in SARS- CoV-2 
disease mechanisms as viewed from the Rheumatology 
perspective on how immunity is contributing to severe 
outcomes remains incompletely understood. Future 
studies should endeavour to address pending questions 
such as a better description of host–virus interactions 
across disease spectrum, and differences in immune 
response between mild and severe forms. Another 
important aspect to be further explored is the iden-
tification of new therapeutic targets and the study of 
humoral immune response to vaccination compared with 
infected individuals. This SLR informs the EULAR PtCs 
on COVID-19 pathophysiology and immunomodulatory 
therapies.
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